Calcimimetic agents, vascular calcification prevention 276 Calcium parathyroid hormone regulation Subject Index 357
|
|
- Jacob Hodge
- 5 years ago
- Views:
Transcription
1 Subject Index Advanced glycation end products (AGEs) atherosclerosis role 168 dietary sources 202, 203 formation 168 platelet phosphatidylserine externalization induction 171, 172 signaling 173 toxicity 317 Albumin, removal of protein-bound solutes Alcohol, cardiovascular disease risks in dialysis patients 225 Aluminum binders 269, 270 Anemia patients 227, 235 Study management 62, 64 Angiotensin-converting enzyme (ACE) inhibitors, cardiovascular disease benefits in hemodialysis patients 4 Anthropometry, total body water estimation 159 Apo E4, cardiovascular disease risks in dialysis patients 223 Arterial compliance definition 307, 308 flow-mediated dilatation 309 pulse wave analysis aortic pressure reconstruction 312 aortic pulse analysis 311, 312 augmentation index 312, 313 finger plethysmography 312 physiological considerations 310 tonometry 312 transfer function 311 pulse wave velocity Artificial kidney, see Wearable artificial kidney Atherosclerosis advanced glycation end product role 169 malnutrition, inflammation, and atherosclerosis syndrome 200, 201 oxidative stress role platelet phosphatidylserine externalization role 169 vascular calcification, see Vascular calcification Beta-blockers, cardiovascular disease benefits in hemodialysis patients 5 Biocompatibility, cardiovascular disease risks in dialysis patients 234 Bioelectrical impedance analysis (BIA), see also Segmental bioimpedance body fluid volume assessment equations 153, 154 techniques 152 definition 163 electrical properties of tissues 151, 152 postdialysis target body weight optimization 150, 151 spectroscopy
2 vector bioelectrical impedance analysis accuracy 154 impedance correlation with ultrafiltration 159 optimal current frequency 159 principles tissue hydration classification 158, 159 vector patterns adequate versus inadequate vector trajectories 158 hemodialysis cycle 155, 156 normal versus abnormal vector trajectories steady state 154, 155 volume-dependent hypertension and hypotension 159 wet-dry weight prescription 160 Biopharmaceutical definition 289 generic versions, see Biosimilars immunogenicity 291, 292 production and characterization 290, 291 stability 291 structural complexity 289, 290 Biosimilars definition 289 regulation 292, 293 Blood flow, control and monitoring in hemodialysis 25 Blood viscosity, shear rate effects Body size, HEMO Study subgroup analysis 75 Body weight obesity and cardiovascular disease risks in dialysis patients 224 postdialysis target body weight optimization, see Bioelectrical impedance analysis Bone morphogenetic protein-7 (BMP-7), deficiency and vascular calcification 281, 282 Calcimimetic agents, vascular calcification prevention 276 Calcium parathyroid hormone regulation vascular calcification, see Vascular calcification Calcium channel blockers, cardiovascular disease benefits in hemodialysis patients 5 3-Carboxy-4-methyl-5-propyl-2- furanpropionic acid (CMPF) morbidity role in dialysis 177, 178 removal of protein-bound solute 178, 179 Central venous pressure, total body water estimation 159, 160 Coffee, caffeine consumption and cardiovascular mortality in dialysis patients 204, 205 Congestive heart failure (CHF), slow continuous intravenous plasmapheresis clinical feasibility study Continuous renal replacement therapy (CRRT) advantages 325, 326 artificial kidney, see Wearable artificial kidney slow continuous intravenous plasmapheresis, see Slow continuous intravenous plasmapheresis slow continuous ultrafiltration, see Slow continuous ultrafiltration Convection diffusion interference 15, 16 solute convective flux equation 122 C-reactive protein (CRP) cardiovascular disease direct promotion by C-reactive protein risk detection end-stage renal disease 189, 190 general population 188, 189 gene polymorphisms 191, 192 interleukin-6 level correlation in end-stage renal disease 186 statin reduction 189, p-cresol patients 234 morbidity role in dialysis 177, 178, 318, 319 removal of protein-bound solute Subject Index 357
3 Depression cardiovascular disease impact in hemodialysis patients 3, 226 Study findings 65 Diabetes, cardiovascular disease risks in dialysis patients 224 Dialysate channeling prevention 15 control and monitoring composition flow 25 delivery system 20, 21 water quality, see Water treatment Study (DOPPS) anemia management 62, 64 background 58, 59, 94, 95 depression findings 65 nutrition and mineral metabolism practices statin outcomes 64, 65 vascular access use and outcomes 65, 66 Dialysis Outcomes Quality Initiative (DOQI), development 94 Diet, see Nutrition Diffusion convection interference 15, 16 diffusivity coefficient 12, 13 effects on sieving 12, 13 solute diffusive flux equation 12 Dilutometry, total body water estimation 160 Dinucleoside polyphosphates, uremic toxicity 320 Dyslipidemia, cardiovascular disease risks in dialysis patients 223, 224, 234 Electrocardiography, potassium removal rates and arrhythmia effects 297, 299, 300, 302, 303 End-stage renal disease (ESRD) cardiovascular mortality 92 demographic trends 6, 91 epidemiology 90, 91 geographic distribution 91 mortality determinants 92, 93 Exercise, inactivity and cardiovascular disease risks in dialysis patients 225 Extracorporeal circuit hemoconcentration measurement 38 overview pressure measurement 39, 40 solute concentration measurement local measurement 36 perturbation 36, 37 resolution 36 sampling rate 36 sodium 37, 38 temperature monitoring 38, 39 Fetuin, see 2 -Heremans-Schmid glycoprotein Fluid overload, cardiovascular disease risks in dialysis patients 222, 223 Generic drug, definition Hemodiafiltration (HDF), see also Mid-dilution hemodiafiltration advantages 108 hemodialysis comparison studies 112 predilution versus postdilution 108, 109 sequential hemofiltrationhemodiafiltration, see Sequential hemofiltration-hemodiafiltration Hemodialysis machines, see also Extracorporeal circuit control and monitoring 24, 25 dialysate delivery system 20, 21 disinfection 22 extracorporeal circuit hazards and safety overview 18, 19 ultrafiltration control 21, 22, 25 Hemofiltration (HF) advantages 52 comparative trial with ultrapure bicarbonate dialysis blood chemistry intratreatment hemodynamics 54, 57 morbidity 54, 57 study design 52, 53 survival 53, 54 Subject Index 358
4 sequential hemofiltrationhemodiafiltration, see Sequential hemofiltration-hemodiafiltration HEMO Study background dialysis dose expressions 77, 78 high-flux dialysis findings 84 86, 11 secondary end points subgroup analysis body size 75 comorbidity 72, 73 prevalent versus incident patients 74, 75 sex differences 75, Heremans-Schmid glycoprotein (AHSG), deficiency and vascular calcification 282, 283 Homocysteine patients 204, 221, 222 vitamin D deficiency and secondary hypertension 268 Infection, cardiovascular disease risks in dialysis patients 227, 228 Inflammation, see also C-reactive protein patients 185, 186, 227, 228 causes in end-stage renal disease 190, 191 genetic susceptibility in end-stage renal disease 191, 192 malnutrition, inflammation, and atherosclerosis syndrome 200, 201 nutrition interactions diet effects on inflammation inflammation effect on nutritional status 201, 202 pathogenesis 201 statin reduction 189, water quality effects 42, 43 Interleukin-6 (IL-6) C-reactive protein level correlation in end-stage renal disease 186 gene polymorphisms 191 Internal filtration (IF) governing principles mathematical modeling applications 34 design and implementation 30, 31 simulations Interventional nephrology (IN) challenges 135, 136 needs 132, 133 overview 131, 132 percutaneous balloon angioplasty access stenosis management 143, 144 complication rates 146, 147 percutaneous bone biopsy 134, 135 peritoneal dialysis catheter placement 133, 134 professional organizations 135 program establishment 133 renal ultrasound 133 thrombectomy for access thrombosis 144, 145 tunneled catheter procedures 134, 145, 146 vascular access responsibilities complication management 127, 128, 134, documentation and quality measures 128, 129 education and training 129 first access placement 123, 126, 127, 134 organization of care 128 patient education 139, 140 planning 140 predialysis period access surgeon referral 122, 123 ultrasound evaluation 122, 126 surveillance and monitoring 123, 124 vascular mapping Kidney Disease: Improving Global Outcomes (KDIGO) development goals 95 website 96 Kidney Disease Outcomes Quality Initiative (K/DOQI), development 94 KoA definition 11 variation with flow distribution 12 Subject Index 359
5 Kt/V control and monitoring 25 inadequacy and cardiovascular disease risks in dialysis patients 224 long nocturnal hemodialysis 104 wearable artificial kidney 330, 331 Lanthanum carbonate, vascular calcification prevention 276 Left ventricular hypertrophy (LVH), kidney disease relationship 93 Leptin patients 234 malnutrition role in hemodialysis patients 202 morbidity role in dialysis patients 177 Lipopolysaccharide (LPS) effects on monocyte phenotype and apoptosis endotoxin removal from dialysis water 235 Lipoprotein(a), cardiovascular disease risks in dialysis patients 223 Long nocturnal hemodialysis Kt/V 104 morbidity mortality 101, 102, 104 rationale 100 study design 101 switching to short hemodialysis 103 Matrix Gla protein (MGP), deficiency and vascular calcification 283, 284 Mediterranean diet, cardiovascular benefits 205 Membraneless dialysis ambulatory dialyzer prospects apparatus performance 349 concept 344 microfluidic transport molecular transport studies in blood 351 plasmapheresis prospects 351 preventing cells from sheath fluid entry 348 recirculating sheath concept Membrane Permeability Outcome (MPO) study background 87 baseline data analysis 87, 88 Membranes cardiovascular risk factor 234, 235 functions 344 limitations in dialysis 344 Mid-dilution hemodiafiltration (MD HDF) advantages compared with high-flux hemodialysis 112, 113 clearance outcomes 110 rationale 108, 109 study design 109, 110 Monocytes apoptosis 212, 213 CD14 expression in hemodialysis 211, 213, 215 CD16 expression in hemodialysis 211, 213 cytokine measurements 211, 213 lipopolysaccharide effects on phenotype and apoptosis telomere shortening and senescence in hemodialysis flow cytometry overview 209, 210 Mortality determinants in end-stage renal disease 92, 93 hemodialysis patients 2, 3, 83, 84, 296 long nocturnal hemodialysis 101, 102, 104 Nocturnal hemodialysis, see Long nocturnal hemodialysis Nutrition advanced glycation end product intake 202, 203 caffeine reduction 204, 205 Nutrition (continued) Study practices inflammation interactions diet effects on inflammation inflammation effect on nutritional status 201, 202 isoflavones 205 Subject Index 360
6 malnutrition, inflammation, and atherosclerosis syndrome 200, 201 omega-3 fatty acids and cardiovascular disease prevention in dialysis patients 225 uremic malnutrition and cardiovascular disease risks in dialysis patients 226, 227 vitamins 203, 204 Obesity, cardiovascular disease risks in dialysis patients 224 Oxidative stress, see also Reactive oxygen species antioxidant defenses 249, 250 biomarkers cell damage mechanisms 245, 246 nutrition and inflammation interactions 203, 204 pathogenesis Alzheimer s disease 256 atherosclerosis autoimmune disease 257 stroke 256, 257 uremic syndrome 253, 254, 256 reactive oxygen species contributors 244, 245 signaling Ozone formation 242 Parathyroid hormone (PTH) calcium regulation derangements and cardiovascular disease risks in dialysis patients 6, 226 elevation in renal failure 267, 268 phosphate regulation 262 renal osteodystrophy management 269, 270 Phenylacetic acid, uremic toxicity 319, 320 Phosphate binders 264, 265, 276 homeostasis control 263, 264 parathyroid hormone regulation 262 parathyroid hyperplasia regulation 262, 263 removal, wearable artificial kidney 331 Platelets, phosphatidylserine externalization advanced glycation end product induction 171 atherosclerosis role 169 end-stage renal disease patients patient serum incubation effects 170 patient studies 170 measurement 169, 170 Potassium derangements and arrhythmias 296, 297 removal rates and arrhythmia effects electrocardiography 297, 299 premature ventricular contractions 299, 300, 302, 303 statistical analysis 299, 304 study design removal, wearable artificial kidney 331 Premature ventricular contractions (PVCs), potassium removal rates and arrhythmia effects 299, 300, 302, 303 Pulse wave analysis aortic pressure reconstruction 312 aortic pulse analysis 311, 312 augmentation index 312, 313 finger plethysmography 312 physiological considerations 310 tonometry 312 transfer function 311 Reactive oxygen species (ROS), see also Oxidative stress antioxidant defenses 249, 250 biological species 241, 242 cell damage mechanisms 245, 246 free radical formation 240, 241 oxidative stress contributors 244, 245 reduction potentials 243, 244 sources 246, 247 Renal osteodystrophy, integrated management 269, 270 Risk factors, cardiovascular disease in dialysis patients, see also specific risk factors dialysis components dialyzer and membrane 234, 235 monitoring 236, 237 treatment modality 235, 236 water quality 235 Subject Index 361
7 Risk factors, (continued) modifiable risk factors potentially modifiable risk factors 227, 228 total risk assessment Scribner, Belding, observations on first hemodialysis 1, 2 Segmental bioimpedance body composition assessment 163, 164 calf measurements 165, 166 definition 163 dry weight assessment Sequential hemofiltration-hemodiafiltration (SHF-HDF) advantages 118, 119 ease of operation 118 rationale 116 study design 116, 117 treatment efficacy quantification 117, 118 Sevelamer, vascular calcification prevention 276 Sheath dialysis, see Membraneless dialysis Slow continuous intravenous plasmapheresis (SCIP) animal studies 335, 336 backflush cycle 340 clinical feasibility study in congestive heart failure indications Slow continuous ultrafiltration (SCUF) animal studies 335, 336 indications 339 Smoking, cardiovascular disease risks in dialysis patients 220, 221 Sodium, measurement in extracorporeal circuit 37, 38 Solute clearance, factors affecting it 11 Soy, cardiovascular benefits 205 Statins cardiovascular disease benefits in hemodialysis patients 4 Study outcomes 64, 65 inflammation reduction 189, Stress, cardiovascular disease risks in dialysis patients 226 Telomere shortening cellular senescence 209 monocytes in hemodialysis flow cytometry overview 209, 210 Ultrafiltration (UF) control and monitoring 21, 22, 25, 236, 237 mechanisms along low-flux and high-flux dialyzers 28, 29 Ultrasound renal ultrasound 133 vascular access evaluation 122, 126 vascular calcification 274 Uremia definition 175 oxidative stress role in uremic syndrome 253, 254, 256 protein-bound solutes in uremic syndrome removal role toxicity 318, 319 toxins and toxicity advanced glycation end products 318 dinucleoside polyphosphates 320 guanidino compounds peptides 320, 321 phenylacetic acid 319, 320 Vascular access (VA) Study use and outcomes 65, 66 interdisciplinary approach 125 nephrologist responsibilities, see also Interventional nephrology complication management 127, 128 documentation and quality measures 128, 129 education and training 129 first access placement 123, 126, 127 organization of care 128 predialysis period access surgeon referral 122, 123 ultrasound evaluation 122, 126 surveillance and monitoring 123, 124 prospects for study 129, 130 Subject Index 362
8 Vascular calcification cardiovascular mortality outcomes 274, 275 detection 274 distribution within artery 272 pathology and etiopathogenesis bone morphogenetic protein-7 deficiency 281, Heremans-Schmid glycoprotein deficiency 282, 283 matrix Gla protein deficiency 283, 284 overview 273, 274, 280, 281, 284, 285 prevention calcimimetic agents 276 calcium-based phosphate binders 276 lanthanum carbonate 276 Sevelamer 276 Vector bioelectrical impedance analysis, see Bioelectrical impedance analysis Vitamin C, deficiency and inflammation 203 Vitamin D deficiency and secondary hypertension 268 resistance in renal failure 268, 269 Vitamin E, cardiovascular disease benefits in hemodialysis patients 6 Water treatment AAMI (Association for the Advancement of Medical Instrumentation) standards patients 235 disinfection 48 European Pharmacopoeia standards inflammation and water quality 42, 43 optimal system 45, 46 quality assurance 48 reverse osmosis 45, 46 ultrapure dialysate preparation 46, 47 Wearable artificial kidney (WAK) animal studies 327, 328 designs 329, 330 limitations 329 mineral removal 330, 331 requirements 326, 327 weekly Kt/V 330, 331 Subject Index 363
9
Gambrosol Trio, clinical studies 91 Glitazone, malnutrition-inflammationatherosclerosis
Subject Index Acidosis, see Metabolic acidosis Activated carbon, sorbents 337 Adipokines adipose tissue and systemic inflammation 169 functions 167 169 prospects for study in renal patients 171 Adiponectin,
More informationHEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI
HEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI high-flux Hemodiafiltration (HDF) Combination of two dialysis techniques, hemodialysis and hemofiltration:
More informationHemodiafiltration: principles and advantages over conventional HD. Rukshana Shroff Great Ormond Street Hospital for Children London, UK
Hemodiafiltration: principles and advantages over conventional HD Rukshana Shroff Great Ormond Street Hospital for Children London, UK Effectiveness of RRT modalities Mcfarlane, Seminars in dialysis, 2009
More informationEFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey
EFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey Chair: Walter H. Hörl, Vienna, Austria Wojciech Zaluska, Lublin, Poland Prof Ercan Ok Division
More informationEnd-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology
End-Stage Renal Disease Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology ESRD : Life with renal replacement therapy CASE: 18 month old male with HUS develops ESRD PD complicated
More informationHemodiafiltration: practical points. Rukshana Shroff Great Ormond Street Hospital for Children London, UK
Hemodiafiltration: practical points Rukshana Shroff Great Ormond Street Hospital for Children London, UK Effectiveness of RRT modalities Mcfarlane, Seminars in dialysis, 2009 No benefit from increased
More informationGeriatric Nutritional Risk Index, home hemodialysis outcomes 131
Subject Index Aksys PHD system 113 Anemia, home outcomes 111, 172, 173 Automated peritoneal dialysis dialysis comparison 17, 18 selection factors 18, 19 telemedicine system 19 21 Blood pressure -peritoneal
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationSUBJECT INDEX. Tvedegaard, E., 20. Ulerich, L., E1 (July) Wapensky, T., 45 Warner, J., 116 Warsaba, D., 52
268 Supasyndh, O., 134 Suraci, C., 208 Tatangelo, P., 208 Tavares, I., 157 Tozzo, C., 208 Tvedegaard, E., 20 Ulerich, L., E1 (July) Wapensky, T., 45 Warner, J., 116 Warsaba, D., 52 Wells, L.M., 26 Winkler,
More informationThere are no shortcuts to Dialysis
There are no shortcuts to Dialysis 1 Outcomes John Sweeny Wednesday, March 21 st, 2018 (3:10 pm 4:10 pm) 2 Quality in Hemodialysis Quality Health Care is the degree to which health services increases the
More informationMaher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University
Hypertension in Hemodialysis Patient Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Mechanism of HTN in HD patients Volume-dependent HTN ECV expansion. Volume-independent HTN
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationThe Role of Dialyzers in Cardiac Protection. Prof. Dr. Eng. Jörg Vienken BioSciences, Fresenius Medical Care, Bad Homburg, Germany
The Role of Dialyzers in Cardiac Protection Prof. Dr. Eng. Jörg Vienken BioSciences, Fresenius Medical Care, Bad Homburg, Germany With a Sense for Details! 1999 Peter Vienken, 11 years Prof. Pim Kolff,
More informationAdvances in Hemodialysis Techniques
Chapter 20 Advances in Hemodialysis Techniques Ayman Karkar Additional information is available at the end of the chapter http://dx.doi.org/10.5772/52444 1. Introduction Hemodialysis (HD) is a technique
More informationModes of Extracorporeal Therapies For ESRD Patients
Modes of Extracorporeal Therapies For ESRD Patients Suhail, MD Extracorporeal Therapies: Dialytic Therapies Dialysis: Movement of molecules across a semipermeable membrane (Bi-directional) Movement of
More informationDrug Use in Dialysis
(Last Updated: 08/22/2018) Created by: Socco, Samantha Drug Use in Dialysis Drambarean, B. (2017). Drug Use in Dialysis. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. DIALYSIS
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationIN THE NAME OF GOD Uremic toxins I. Small (< 500 D); water soluble Surrogate marker urea or sodium (ionic dialysance) Rapidly produced in intracellular fluid compartment Large variability in intra-patient
More informationOlistic Approach to Treatment Adequacy in AKI
Toronto - Canada, 2014 Olistic Approach to Treatment Adequacy in AKI Claudio Ronco, MD Department of Nephrology, St. Bortolo Hospital, International Renal Research Institute Vicenza - Italy 1) RRT
More informationKaren Mak R.N. (Team Leader) Renal Dialysis Centre Hong Kong Sanatorium & Hospital
Karen Mak R.N. (Team Leader) Renal Dialysis Centre Hong Kong Sanatorium & Hospital - Renal Transplantation - Peritoneal Dialysis - Extracorporeal Therapy Extracorporeal Therapy It is the procedure in
More informationAchieving Equilibrium in ESRD Patients
Achieving Equilibrium in ESRD Patients -Marc Richards MD -South Florida Kidney Disease and HTN Specialists -Chief of Medicine, BRRH -BRRH Grand Rounds: April 18 th, 2017 Outline Dialysis prescription Adequacy
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationHEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS 1.0 PRACTICE CONSIDERATIONS 2.0 CURRENT LITERATURE REVIEW
HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS This document was prepared at the request of the BC Hemodialysis Committee to provide a brief overview of the literature and to identify
More informationECMO & Renal Failure Epidemeology Renal failure & effect on out come
ECMO Induced Renal Issues Transient renal dysfunction Improvement in renal function ECMO & Renal Failure Epidemeology Renal failure & effect on out come With or Without RRT Renal replacement Therapy Utilizes
More informationHDx THERAPY. Enabled by. Making possible personal.
HDx THERAPY Enabled by Making possible personal. THE NEXT HORIZON IN DIALYSIS IS CLOSER THAN YOU THINK PHOSPHATE UREA HDx BY THERANOVA EXPANDS YOUR RENAL POSSIBILITIES The new HDx therapy (expanded HD)
More informationHemodialysis is a life-sustaining procedure for the treatment of
The Dialysis Prescription and Urea Modeling Biff F. Palmer Hemodialysis is a life-sustaining procedure for the treatment of patients with end-stage renal disease. In acute renal failure the procedure provides
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationHemodiafiltration in Europe : Trends, Practices, Outcomes & Perspectives
Hemodiafiltration in Europe : Trends, Practices, Outcomes & Perspectives Prof. Bernard Canaud Nephrology, Dialysis and Intensive Care Lapeyronie Hospital CHRU Montpellier - France Opening remarks and special
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationObjectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring
Peritoneal Dialysis Prescription and Adequacy Monitoring Christine B. Sethna, MD, EdM Division Director, Pediatric Nephrology Cohen Children s Medical Center Associate Professor Hofstra Northwell School
More informationSelected age-associated changes in the cardiovascular system
Selected age-associated changes in the cardiovascular system Tamara Harris, M.D., M.S. Chief, Interdisciplinary Studies of Aging Acting Co-Chief, Laboratory of Epidemiology and Population Sciences Intramural
More informationSection 3: Prevention and Treatment of AKI
http://www.kidney-international.org & 2012 KDIGO Summary of ommendation Statements Kidney International Supplements (2012) 2, 8 12; doi:10.1038/kisup.2012.7 Section 2: AKI Definition 2.1.1: AKI is defined
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationSubject Index. (A) = Abstracts, 5th Annual Meeting of the International Society of Blood Purification.
Subject Index (A) = Abstracts, 5th Annual Meeting of the International Society of Blood Purification. Acute hepatic failure, artificial supports 313(A) Acute renal failure - - -, arteriovenous hémodiafiltration
More informationPediatric Nutrition and Kidney Disease
Pediatric Nutrition and Kidney Disease Loai Eid, MD, MSHS, FAAP Consultant Pediatric Nephrologist Pediatric Nephrology & Hypertension Division Chief Dubai Hospital - DHA 26 th October, 2017 Objectives
More informationContinuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationMODALITIES of Renal Replacement Therapy in AKI
MODALITIES of Renal Replacement Therapy in AKI Jorge Cerdá, MD, MS, FACP, FASN Clinical Professor of Medicine Albany Medical College Albany, NY, USA cerdaj@mail.amc.edu In AKI, RRT is a multidimensional
More informationStefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K.
Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece Passive, degenerative accumulation process of Ca ++ /P +++ without treatment options Active, complex, condition:
More informationHemodialysis Adequacy: A Complex and Evolving Paradigm. Balazs Szamosfalvi, MD Monday, 08/30/ :00-09:45
Hemodialysis Adequacy: A Complex and Evolving Paradigm Balazs Szamosfalvi, MD Monday, 08/30/2010 09:00-09:45 Adequacy 1943-1970 Fresenius The patient survived the dialysis session Uremia improved Volume
More informationContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationCardiorenal Syndrome
Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural
More informationAna Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto
Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate
More informationHow to deal with hypotension on dialysis? CME Basics in Nephrology SGN-SSN Interlaken 2016
How to deal with hypotension on dialysis? CME Basics in Nephrology SGN-SSN Interlaken 2016 PD Dr. med. Andreas Kistler Leitender Arzt Nephrologie und Dialyse Kantonsspital Frauenfeld www.spital-thurgau.ch
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationOriginal epidemiologic studies 1 have suggested that approximately
Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of
More informationFundamentals of DIALYSIS
Fundamentals of DIALYSIS Knowing Your Kidneys Healthy Kidneys are the body s cleaning crew These are twin bean shaped organs, of the size of fist They make up a filter system for the blood & reabsorb almost
More informationSpecific Basic Standards for Osteopathic Fellowship Training in Nephrology
Specific Basic Standards for Osteopathic Fellowship Training in Nephrology American Osteopathic Association and American College of Osteopathic Internists BOT Rev. 2/2011 These specific basic standards
More informationTHE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE
THE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE THE DIALYSIS CYCLE /TIME DESIGN OF THE NATIONAL COOPERATIVE DIALYSIS STUDY
More informationLONG-TERM HEMODIALYSIS
LONG-TERM HEMODIALYSIS LONG-TERM HEMODIAL YSIS N.K. Man H6pital Ncckcr. Dcpartement ele Ncphrologie. Paris. Francc.J. Zingraff H6pital Necker. Dcparlcmenl de Nephrologie. Paris. France and P. Jungers H6pital
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More information- SLED Sustained Low-Efficiency Dialysis
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms - SCUF - Slow Continuous Ultrafiltration
More informationCKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology
CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR
More informationWhat is renal failure?
What is renal failure? The kidney is a very important organ, and cannot be restored to health once it fails. However, it is possible to avoid or retard the deterioration of its functionality if therapy
More informationPrevalence of Access Recirculation in Prevalent Arterio-Venous (A-V) Fistula Hemodialysis Patients and Its Effect on Hemodialysis Adequacy
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (6), Page 4602-4609 Prevalence of Access Recirculation in Prevalent Arterio-Venous (A-V) Fistula Hemodialysis Patients and Its Effect on Hemodialysis
More informationPrescriptions for Home Hemodialysis
9 Prescriptions for Home Hemodialysis Robert Lockridge, MD 1 Tom Cornelis, MD 2 Carolyn van Eps, MBBS, PhD, FRACP 3 1 Lynchburg Nephrology Physicians, Lynchburg, Virginia, USA; 2 Department of Internal
More informationONLINE HEMODIALYSIS TRAINING SESSION 1
ONLINE HEMODIALYSIS TRAINING SESSION 1 This document is a supplement to the Online Training. Do not reproduce. Copyright Dialysis4Career. All Rights Reserved. The Renal System - A highly sophisticated
More informationOn Referral to our Unit
Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient
More informationTiming, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement
Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement Prof. Dr. Achim Jörres Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum
More informationCRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT
CRRT Fundamentals Pre-Test AKI & CRRT 2017 Practice Based Learning in CRRT Question 1 A 72-year-old man with HTN presents to the ED with slurred speech, headache and weakness after falling at home. He
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More informationDual-energy X-ray absorptiometry (DXA), body composition assessment 62
Subject Index 3 -Adrenergic receptor, gene polymorphisms and obesity 10 Aging, body composition effects 64, 65 Air-displacement plethysmography, body composition assessment 62 Bioelectrical impedance analysis
More informationPhysiology of Blood Purification: Dialysis & Apheresis. Outline. Solute Removal Mechanisms in RRT
Physiology of Blood Purification: Dialysis & Apheresis Jordan M. Symons, MD University of Washington School of Medicine Seattle Children s Hospital Outline Physical principles of mass transfer Hemodialysis
More information28-Feb-10 Reza Sabagh
DIALYSIS EQUIPMENTS (DIALYSIS MACHINE & R.O) Nursing Conference on Dialysis Tehran 1 The standard dialysis machines are designed for performing chronic and acute hemodialysis. They can be used in home
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Guideline (2010) Chronic Kidney Disease CKD: Executive Summary of Recommendations (2010) Executive Summary of Recommendations Below are the major recommendations
More informationoxiris A single CRRT set with multiple benefits for managing critically ill patients with AKI Adsorption of inflammatory mediators
oxiris A single CRRT set with multiple benefits for managing critically ill patients with AKI Adsorption of inflammatory mediators Heparin-grafted for reduced thrombogenicity Supports renal function POWERED
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Blood urea sampling methods GUIDELINES
Date written: November 2004 Final submission: July 2005 Blood urea sampling methods GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions are
More informationPRE-DIALYSIS CARE IN CHRONIC KIDNEY DISEASE PATIENTS DR O. A ADEJUMO MBBS, FWACP, FMCP
PRE-DIALYSIS CARE IN CHRONIC KIDNEY DISEASE PATIENTS DR O. A ADEJUMO MBBS, FWACP, FMCP OUTLINE INTRODUCTION BURDEN OF CKD DEFINITION OF PRE-DIALYSIS CARE (PDC) GOALS OF PDC IN CKD COMPONENTS OF PDC ADVANTAGES
More informationComplications observed in end-stage renal disease may be due to
Complications of Dialysis: Selected Topics Robert W. Hamilton Complications observed in end-stage renal disease may be due to the side effects of treatment or to the alterations of pathophysiology that
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationHemodialysis: slightly beyond basics Dialysate calcium and magnesium concentrations
Dialysate calcium and magnesium concentrations Stefan Farese Department of Nephrology Bürgerspital Solothurn 04.12.2013 Dialysate calcium and magnesium concentrations Do we know the optimal concentrations?
More informationCalcium Management for Patients Receiving Extended Duration Hemodialysis
Calcium Management for Patients Receiving Extended Duration Hemodialysis Created November 2017; Updated March 2018 Approved by the BCPRA Home Hemodialysis Committee Table of Contents 1.0 Practice Standard...1
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationNurse-Pharmacist Collaboration in the Delivery of Continuous Renal Replacement Therapy
Cedarville University DigitalCommons@Cedarville Pharmacy Faculty Presentations School of Pharmacy 2-23-2012 Nurse-Pharmacist Collaboration in the Delivery of Continuous Renal Replacement Therapy Jeb Ballentine
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationHemodiafiltration in BC Current Status and Obstacles Myriam Farah, MD, FRCPC
2015 emodiafiltration in BC Current Status and Obstacles Myriam Farah, MD, FRCPC OUTLINE What Why ow Why Not What Now No financial disclosures. DF = D and igh volume ULTRAFILTRATION to achieve convective
More informationImplementing therapy-delivery, dose adjustments and fluid balance. Eileen Lischer MA, BSN, RN, CNN University of California San Diego March 6, 2018
Implementing therapy-delivery, dose adjustments and fluid balance. Eileen Lischer MA, BSN, RN, CNN University of California San Diego March 6, 2018 Objectives By the end of this session the learner will
More information2019 Home Hemodialysis Standing Orders
2019 Home Hemodialysis Standing Orders 1. Nutrition Standards of Care: A. Follow P&P Nutrition Standards of Care 2. Laboratory Tests: A. Drawn On Admission: 1. Renal Function Panel (BMP, PO 4 and Albumin)
More informationCommission of Dietetic Registration Board Certified Specialist in Renal Nutrition Certification Examination Content Outline
I. Nutrition Assessment and Re-assessment (36%) A. Food/Nutrition-Related History 1. Evaluate current nutrition intake, losses, and nutrient adequacy. 2. Assess nutritional needs related to ethnic and
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationDiacap. Constant performance resulting in high quality dialysis. Avitum
Diacap Constant performance resulting in high quality dialysis Avitum B. Braun Avitum. Always with Passion. B. Braun is a leading international company in the healthcare market. With a long tradition stretching
More informationCITRATE DIALYSIS FLUID
CITRATE DIALYSIS FLUID Making possible personal. A CITRATE CONTAINING DIALYSIS FLUID FREE OF ACETATE The Gambro SoftPac concentrate is a citrate-containing, acetate-free concentrate developed by Gambro
More informationCRRT Fundamentals Pre- and Post- Test. AKI & CRRT Conference 2018
CRRT Fundamentals Pre- and Post- Test AKI & CRRT Conference 2018 Question 1 Which ONE of the following statements regarding solute clearance in CRRT is MOST correct? A. Convective and diffusive solute
More informationCan We Achieve Precision Solute Control with CRRT?
Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationHemodialysis today has evolved
Lessons in Dialysis, Dialyzers, and Dialysate Robert Hootkins, MD, PhD The author is Chief of Nephrology and Hypertension at The Austin Diagnostic Clinic, Austin, Texas. He is also a member of D&T s editorial
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationKrediet slide di 18
1 di 18 Assessment of fluid status in PD patients Raymond T. Krediet, Amsterdam, Netherlands Chairs:Walther H. Boer, Utrecht, The Netherlands F. Fevzi Ersoy, Antalya, Turkey Prof. Raymond T. Krediet DDivision
More informationDialysers Increasing Cost and Treatment Efficiency
Haemodialysis Dialysers Increasing Cost and Treatment Efficiency Fluid Substitution Calculator Content Haemodialysis yesterday 3 Haemodialysis today 4 Dialyser selection criteria 5 Relation of blood flow
More informationPediatric Continuous Renal Replacement Therapy
Pediatric Continuous Renal Replacement Therapy Farahnak Assadi Fatemeh Ghane Sharbaf Pediatric Continuous Renal Replacement Therapy Principles and Practice Farahnak Assadi, M.D. Professor Emeritus Department
More informationHemodialysis Fistula Maturation Consortium
Hemodialysis Fistula Maturation Consortium Rationale for Fistula Maturation Study Dialysis Access Consortium AVF study 60% of new AVFs were unusable for dialysis at 4-5 months post surgery No predictors
More information